¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"T cell growth factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blast cell
    ¸ð¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • balloon cell nevus
    dz¼±¼¼Æ÷¸ð¹Ý
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
  • ciliated cell
    ¼¶¸ð¼¼Æ÷
  • clear cell
    Åõ¸í¼¼Æ÷
  • clear cell acanthoma
    Åõ¸í¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, Åõ¸í¼¼Æ÷±Ø¼¼Æ÷Á¾
  • clear cell adenocarcinoma
    Åõ¸í¼¼Æ÷»ù¾ÏÁ¾, Åõ¸í¼¼Æ÷¼±¾ÏÁ¾
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • basal cell nevus
    ¹Ù´Ú¼¼Æ÷¸ð¹Ý, ±âÀú¼¼Æ÷¸ð¹Ý
  • basal cell nevus syndrome
    ¹Ù´Ú¼¼Æ÷¸ð¹ÝÁõÈıº, ±âÀú¼¼Æ÷¸ð¹ÝÁõÈıº
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
  • cell bank
    ¼¼Æ÷ÀºÇà
  • nerve cell body
    ½Å°æ¼¼Æ÷ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • Henle s cell
    Çî·¯¼¼Æ÷.
  • Hfr cell
    °íºóµµÀçÁ¶ÇÕ¼¼Æ÷
  • Hulle cell
    ¿ÜÇǼ¼Æ÷
  • ICSH = interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±Ø(Êàòõá¬øàí©Ð½)È£¸£¸ó.
  • ICSH=£¾interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó.
  • K cell
    K¼¼Æ÷, »ìÇØ¼¼Æ÷
  • LE cell
    LE¼¼Æ÷.
  • LE cell phenomenon
    LE¼¼Æ÷Çö»ó.
  • Langerhans cell
    ¶û°Ô¸£Çѽº¼¼Æ÷.
  • Langerhans cell histiocytosis
    ¶û°Ô¸£Çѽº ¼¼Æ÷ Á¶Á÷±¸Áõ
  • Langerhans cell histiocytosis
    ¶û°Ô¸£Çѽº¼¼Æ÷Á¶Á÷±¸Áõ
  • Langerhans giant cell
    ¶û±×Çѽº°Å¼¼Æ÷
  • Langhans giant cell
    ¶û±×Çѽº°Å´ë¼¼Æ÷
  • Leydig cell
    ·¹À̵ðÈ÷ ¼¼Æ÷
  • Leydig cell adenoma
    ·¹À̵ðÈ÷¼¼Æ÷¼±Á¾
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • common factor
    °øÅëÀÎÀÚ(Íì÷×ì×í­).
  • competence factor
    Àû°Ý¼ºÀÎÀÚ
  • competence inducing factor
    Àû°ÝÀ¯¹ßÀÎÀÚ(îêÌ«ë¯Û¡ì×í­).
  • complementary factor
    º¸ÃæÀÎÀÚ(¡­ì×í­), º¸Ã¼ÀÎÀÚ.
  • conglutinogen activating factor
    ±³Âø¿ø (conglutinogen, factor IÀÇ ¿¾¸»)
  • conversion factor
    º¯È¯ ÀÎÀÚ
  • cooperative factor
    Çùµ¿ÀÎÀÚ.
  • cord factor
    ±Õ»öÀÎÀÚ
  • cord factor
    ÄÚ¿Àµå ÀÎÀÚ(¡­ì×í­)
  • cord factor
    ÄÚ¿ÀµåÀÎÀÚ(¡­ì×í­).
  • coronary risk factor
    °ü(»ó)(µ¿¸Æ)ÁúȯÀ§Çè¿äÀÎ.
  • corticotropin-releasing factor =CRF
    ºÎ½ÅÇÇÁú ÀÚ±ØÈ£¸£¸ó ¹æÃâÀÎÀÚ(Üù ãìù«òõô§Ð½¡­Û¯õóì×í­).
  • cothromboplastin factor VII
    ÄÚÆ®·Òº¸ÇÃ¶ó½ºÆ¾.
  • coupling factor
    ¹è¿ìÀÎÀÚ.
  • covering factor
    ÇǺ¹ÀÎÀÚ(¡­ì×í­).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • hypercalcemic factor
    °ú(Φ)Ä®½·Ç÷Áõ(úìñø) ÀÎÀÚ(ì×í­)
  • hyperglycemic factor
    °úÇ÷´ç ÀÎÀÚ(ΦúìÓØì×í­)
  • hypocalcemic factor
    Àú(î¸)Ä®½·Ç÷Áõ(úìñø) ÀÎÀÚ(ì×í­)
  • hypoglycemic factor
    ÀúÇ÷´ç ÀÎÀÚ(î¸úìÓØì×í­)
  • initiation factor
    °³½ÃÀÎÀÚ(ËÒã·ì×í­)
  • instability factor
    ºÒ¾ÈÁ¤ÀÎÀÚ(ÝÕäÌïÒì×í­)
  • integration host factor
    ÅëÇÕ ¼÷ÁÖÀÎÀÚ(÷ÖùêâÖñ«ì×í­)
  • intrinsic factor
    ³»ÀÎÀÎÀÚ(Ò®ì×ì×í­)
  • labile factor
    ºÒ¾ÈÁ¤ÀÎÀÚ(ÝÕäÌïÒì×í­)
  • Laki-Lorand factor
    ¶óŰ-·Î¶õµå ÀÎÀÚ(ì×í­)
  • Lande G factor
    ¶õµ¥ G ÀÎÀÚ(ì×í­)
  • lard factor
    µ·Áö(ÔÊò·) ÀÎÀÚ(ì×í­)
  • leukocyte inhibitory factor
    ¹éÇ÷±¸ÀúÇØÀÎÀÚ(ÛÜúìϹîÁúªì×í­)
  • Lewis factor
    ·çÀ̽ºÀÎÀÚ(ì×í­)
  • lipoprotein tissue factor
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ) Á¶Á÷ÀÎÀÚ(ðÚòÄì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
bFGF basic fibroblast growth factor
DGF duct growth factor
EGDF embryonic growth and development factor
EGF epidermal growth factor
EGFR, EGF-R epidermal growth factor receptor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
GDF5 Growth/differentiation factor 5
HGF Hematopoietic growth factor
HB-EGF Heparin binding epidermal growth factor
HBGF-1 Heparin binding growth factor 1
HB-EGF Heparin-Binding EGF-like growth factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bristle cell
    °­¸ð ¼¼Æ÷, ¸ð¼¼Æ÷
  • calcigerous cell
    ¼®È¸È­ ¼¼Æ÷
  • cameloid cell
    Ÿ¿øÇü ÀûÇ÷±¸
  • cancer cell
    ¾Ï ¼¼Æ÷
    Á¤»óÀÎ Á¶Á÷ ¼¼Æ÷°¡ ¾î¶² ¿øÀÎÀ¸·Î ¹«Á¦ÇÑ Áõ½ÄÇÏ¿© ±× »ýüÀÇ »ýȰÇö»óÀ̳ª ÁÖÀ§ÀÇ Á¶Á÷ »óÅ µî¿¡ °ü°è¾øÀÌ ±Þ¼ÓÇÑ ¹ßÀ°À» °è¼ÓÇÏ¿© ¸¶Ä§³»´Â »ý¸íÀ» ²÷°Ô ÇÏ´Â ¾Ç¼ºÀÇ ½Å»ý¹°À̶ó°íµµ º¼ ¼ö ÀÖ´Â ¼¼Æ÷. ¼¼Æ÷ÇÐÀûÀ¸·Î º¸¸é ±× ¸ð¾çÀ̳ª Å©±â°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ´Ù¼Ò º¯È­µÇ¾î ÀÖ´Ù. Áï, ÇÙÀº ¿°»öü°¡ ¸¹°í, ÇÙÀÇ ¿øÇüÁú¿¡ ´ëÇÑ ºñ°¡ Å©¸ç, ÇÙ¼Òü¸¦ °¡Áö°í, ÀÚÁÖ ÇÙ ºÐ¿­»óÀ» ³ªÅ¸³½´Ù. À̰ÍÀ» ÀÌÇü¼ºÀ̶ó°í ÇÑ´Ù. ÀÌÇü¼ºÀÌ °­ÇÑ °ÍÀÌ ¾Ï ¼¼Æ÷ÀÇ Æ¯Â¡ÀÌ´Ù. À̰ÍÀ» ÀÌ¿ëÇÑ °ÍÀÌ ¼¼Æ÷ÁøÀ̸ç, À§¾Ï µî ¸ðµç ¾ÏÀÇ Á¶±â Áø´Ü¿¡ Å« ¿ªÇÒÀ» Çϰí ÀÖ´Ù. Á¤»ó ¼¼Æ÷°¡ ¾î¶»°Ô ÇØ¼­ ¾Ï ¼¼Æ÷·Î º¯Çϴ°¡´Â ºÒ¸í·áÇÑ Á¡ÀÌ ¸¹Áö¸¸, È÷¸£È¿ÀÇ Àڱؼ³Àº À¯¸íÇÏ´Ù. À̰ÍÀº È­ÇÐÀû, ±â°èÀû, ¹°¸®Àû µîÀÇ ¸¸¼º ÀÚ±ØÀÌ ÀÛ¿ëÇÏ´Â °÷¿¡ ¾ÏÀÌ ¹ß»ýÇÑ´Ù´Â ¼³ÀÌ´Ù. ¹ÙÀÌ·¯½º¿ÍÀÇ °ü°èµµ ±Ù³â¿¡ ÁÖ¸ñÀ» ²ø¾î, F.P. ¶ó¿ì½ºÀÇ ´ßÀÇ À°Á¾ ¹ÙÀÌ·¯½º³ª R.E. ¼îÇÁÀÇ Åä³¢ÀÇ À¯µÎÁ¾ ¹ÙÀÌ·¯½º´Â À¯¸íÇÏÁö¸¸, Àΰ£ÀÇ ¾Ï°ú È®½ÇÇÏ°Ô °ü°è¸¦ °®´Â ¹ÙÀÌ·¯½º´Â ¾ÆÁ÷ ¹ß°ßÇÏÁö ¸øÇϰí ÀÖ´Ù. ¾Ï ¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿Í ´Ù¸¥ Á¡Àº ÀÚÀ²ÀûÀ¸·Î Áõ½ÄÇϰí ÁÖÀ§ÀÇ Á¶Á÷À» ÆÄ±«ÇÏ¿© ħÀ±¼ºÀ¸·Î ¹ßÀ°ÇÏ´Â °Í, ¾Ï ¼¼Æ÷°¡ À¯¸®µÇ¾î ¸²ÇÁÇ༺, Ç÷Ç༺À¸·Î ¿ø°Ý Àå±â¿¡ ÀüÀÌÇÏ´Â °Í, ÆÄÁ¾À̶ó ÇÏ¿© º¹°­³»³ª Èä°­³»ÀÇ Àå±âÀÇ ¾Ï¿¡¼­´Â ¾Ï ¼¼Æ÷°¡ À帷¿¡ µµ´ÞÇÏ¸é º¹¸·À̳ª È丷¿¡ ºÎÂøÇÏ¿© ¹ßÀ°À» °è¼ÓÇÏ´Â °Í µîÀÌ´Ù. ÀÌ·± Ư¼º ¶§¹®¿¡ ¾ÏÀÇ Ä¡·á°¡ º¹ÀâÇØÁö°í Àç¹ßµÇ±â ½±´Ù. µû¶ó¼­ ¾ÏÀ» °íÄ¡·Á¸é ¾Ï ¼¼Æ÷°¡ ÀÌ·± Ư¼ºÀ» ÃæºÐÈ÷ ¹ßÈÖÇÏÁö ¸øÇÏ´Â Á¶±â¿¡ ¹ß°ß, Ä¡·áÇØ¾ß ÇÑ´Ù.
  • capsule cell
    ÇǸ· ¼¼Æ÷, À§¼º ¼¼Æ÷
  • caterpillar cell
    ¸ðÃæ ¼¼Æ÷
  • caveolated cell
    ¼ÒÆ÷¿ò ¼¼Æ÷
    ÈçÈ÷ º¼ ¼ö ÀÖ´Â °ÍÀº ¾Æ´ÏÁö¸¸, ¼ÒÀå, ´ëÀå, À§ µîÀÇ ¿ò°ú À¶¸ð¿¡¼­ º¼ ¼ö ÀÖ´Ù. ²À´ë±âº¸´Ù ¹Ù´Ú ºÎºÐÀÌ ³ÐÀ¸¸ç ²À´ë±â¿¡´Â ¹Ì¼¼ À¶¸ð°¡ Àִµ¥ ±× ¼Ó¿¡´Â ¼¼»ç ´Ù¹ßÀÌ ÇÔÀ¯µÇ¾î ÀÖÀ¸¸ç, ÀÌµé ¼¼»ç ´Ù¹ß »çÀÌ¿¡ ¼¼Æ÷¸·ÀÌ ÇÔÀÔµÈ ¼Ò¿òµéÀÌ ÀÖ´Ù.
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò
    1. »ýü Á¶Á÷ÀÇ ±âº» ´ÜÀ§. Çö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÑ À¯±âü¸¦ ±¸¼ºÇÏ´Â ´Ù¾çÇÑ ¿øÇüÁú µ¢¾î¸® Áß ÇÑ °¡Áö. °¢ ¼¼Æ÷´Â ¼¼Æ÷¸·, ¿øÇüÁú, ÇÙ, ´Ù¾çÇÑ ºÀÀÔü¸¦ °¡Áö°í ÀÖ´Ù. °¢ ¼¼Æ÷ Á¾·ù´Â °¢°¢ÀÇ ´ë»ç ¿ä±¸, ÀÛ¿ë, Åõ°úµµ, ´Ù¸¥ ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â ´É·Â, Àç»ý»ê¼º°ú ¼ö¸íÀ» °¡Áø »ì¾Æ ÀÖ´Â ´ÜÀ§ÀÌ´Ù. 2. »ý¹°ÀÇ ¸öÀ» ±¸¼ºÇÏ´Â ÃÖ¼ÒÀÇ ´ÜÀ§. ¸¹Àº »ý¹°Àº ´Ù¼öÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁ® Àֱ⠶§¹®¿¡ ´Ù¼¼Æ÷ »ý¹°À̶ó°í ÇÏÁö¸¸, ¾î¶² Á¾¿¡¼­´Â ±× ÀÚü°¡ ÇϳªÀÇ ¼¼Æ÷·Î µÇ¾î Àֱ⠶§¹®¿¡ ´Ü¼¼Æ÷»ý¹°À̶ó ÇÑ´Ù. ¼¼±Õ, ±ÔÁ¶, ¹Ý´Þ¸», Ŭ·Î·¼¶ó¿Í °°Àº °£´ÜÇÑ Á¶·ù, ¾Æ¸Þ¹Ù, ¤½Å¹ú·¹¿Í °°Àº ¿ø»ýµ¿¹° µîÀº ´Ü¼¼Æ÷»ý¹°ÀÌ´Ù. º¸Åë µ¿¹°ÀÇ ³­ÀÚ´Â ¹ß»ý Ãʱ⿡´Â ´Ü¼¼Æ÷ÀÌÁö¸¸, °ð ºÐ¿­ÇÏ¿© ´Ù¼¼Æ÷·Î µÈ´Ù. ´«À¸·Î º¸ÀÌ´Â °Í¿¡´Â ¹ß»ý ÃʱâÀÇ µ¿¹°ÀÇ ³­ÀÚ, ½Å°æ¼¼Æ÷
  • cell adhesion molecular deficiency
    ¼¼Æ÷ À¯Âø ºÐÀÚ °áÇÌ
  • cell adhesive matrix assay
    ¼¼Æ÷ Á¡Âø ±âÁú ºÐ¼®
  • cell axon terminal
    ¼¼Æ÷ Ãà»è Á¾¸»
  • cell bound antibody
    ¼¼Æ÷ °áÇÕ Ç×ü
    Ç×ü´Â Fc ºÎÀ§¸¦ °³Àç½ÃÄÑ ¼¼Æ÷ÀÇ Fc ¼ö¿ë±â¿Í °áÇÕÇϴµ¥ ÀϹÝÀûÀ¸·Î ´Üüº¸´Ùµµ ÁßÇÕüÀÎ ÆíÀÌ ¼¼Æ÷¿¡ ´ëÇÑ Ä£È­¼ºÀÌ ³ô¾ÆÁø´Ù. ½ÇÁ¦ÀÇ °áÇÕ ´É·ÂÀº ¸é¿ª ±Û·ÎºÎ¸° class »çÀÌ¿¡¼­ ÇöÀúÇÑ Â÷À̸¦ º¸°Ô µÇ´Âµ¥ ¼¼Æ÷°¡ ´Ù¸£¸é °¢°¢¿¡ ´ëÇÑ Ä£È­¼ºÀÌ º¯È­Çϰí Ç×ü¿Í ¼¼Æ÷ ¾çÂÊÀÇ ¼ºÁúÀÌ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ¾î ÀÖ´Ù. ´Üü Áß¿¡¼­µµ IgE³ª ¼³Ä¡·ù µ¿¹°ÀÇ IgG´Â µ¿Á¾ ģȭ¼º Ç×ü¶ó°í ºÒ¸®¿ì¸ç ¾Ë·¹¸£±â³ª ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÇ ±âÀÎÀÌ µÈ´Ù.
  • cell color ratio
    Ç÷±¸»ö¼Òºñ, ÀûÇ÷±¸ »ö¼Òºñ
  • cell count
    ¼¼Æ÷ ¼ö
    ´ÜÀ§ ºÎÇÇ´ç Æ÷ÇԵǾî ÀÖ´Â ¼¼Æ÷ ¼ö·Î¼­ º¸Åë ´ÜÀ§ ºÎÇÇ´ç Ç÷¾×¿¡ Æ÷ÇԵǾî ÀÖ´Â ÀûÇ÷±¸¿Í/ȤÀº ¹éÇ÷±¸¸¦ ¸»ÇÑ´Ù.
  • cell culture biocompatibility test
    ¼¼Æ÷ ¹è¾ç »ýü ÀûÇÕ¼º °Ë»ç¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
mouse antialopecia factor A member of the vitamin B complex necessary for growth of yeast and of mice, absence from the diet causes hair loss and dermatitis in mice.
(27 Sep 1997)
plasma factor X <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
plasma labile factor <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
Williams factor high molecular weight kininogen
M phase promoting factor Protein whose levels rise rapidly just before and fall away just after, mitosis. Thought to be a trigger for mitosis.
(18 Nov 1997)
plasma thromboplastin factor A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs.
(12 Dec 1998)
plasma thromboplastin factor B <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
plasmin prothrombins conversion factor <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
platelet-activating factor <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis.
It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction.
Synonym: platelet-aggregating factor.
Acronym: PAF
(20 Sep 2002)
platelet-aggregating factor <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis.
It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction.
Synonym: platelet-aggregating factor.
Acronym: PAF
(20 Sep 2002)
platelet factor 3 <haematology> Phospholipid associated with the platelet plasma membrane that contributes to the blood clotting cascade by forming a complex (thromboplastin) with other plasma proteins and activating prothrombin.
(31 Dec 1997)
platelet factor 4 <haematology> Platelet released protein that promotes blood clotting by neutralising heparin.
(31 Dec 1997)
platelet tissue factor <haematology> Traditional name for substance in plasma that converts prothrombin to thrombin. Now known not to be a single substance. (See thrombin).
(18 Nov 1997)
mullerian inhibiting factor A 535 amino acid glycoprotein secreted by the Sertoli cells of the testis. It is related to inhibin.
Synonym: mullerian inhibiting factor.
(05 Mar 2000)
mullerian regression factor Mullerian duct inhibitory factor, a non-steroidal substance of foetal testicular origin that acts unilaterally to inhibit development of the paramesonephric (mullerian) ducts and acts with testosterone to promote development of the vas deferens and related structures.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
ÅëÇÕ°Ë»ö ¿Ï·á